



truscreen
a world without
cervical cancer

NZX/ASX Announcement

11 June 2021

TruScreen Group Limited (NZX and ASX:TRU)

For an interview with TruScreen Chief Executive Officer Juliet Hull with Stocks Down Under please see:

<https://truscreen.com/news/ceo-interview-with-stocks-down-under/>

Authorised for release by the Truscreen Board.

-ENDS-

For more information, visit www.truscreen.com or contact:

Juliet Hull

Chief Executive Officer

juliet@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant.